How is Advate produced?

How is Advate produced?

ADVATE is containing recombinant human antihaemophilic factor VIII (rFVIII; INN: octocog alfa), which is synthesised by a genetically engineered Chinese hamster ovary (CHO) cell line.

How long does Antihemophilic Factor last?

ADVATE should be refrigerated (2° – 8°C [36° – 46°F]) in powder form. ADVATE may be stored at room temperature (up to 30°C [86°F]) for a period of up to 6 months not to exceed the expiration date.

How much does recombinant cost?

Product (Manufacturer) Source Average Cost Per Dose ($)a,b
Recombinate® (Baxter Hyland/Immuno) Recombinant 4,480
Kogenate FS® (Bayer) Recombinant 4,130
Helixate FS® (Aventis Behring) Recombinant 4,130
Refacto® (Genetics Institute) Recombinant 4,760

Is advate a blood product?

In 2003, ADVATE became the first recombinant factor VIII treatment free of blood-based additives. Since then, TAKEDA has made advancements with flexible dosing options, reconstitution with BAXJECT® system, and the introduction of myPKFiT® for PK-guided personalized dosing.

Who makes Kovaltry?

Bayer, the Bayer Cross, Kogenate, Kovaltry and Jivi are registered trademarks of Bayer. Access Services by Bayer is a trademark of Bayer.

What are Antihemophilic agents?

These agents are used to control bleeding in hemophilia B or FIX deficiency and to prevent and/or control bleeding in patients with hemophilia A and inhibitors to FVIII. These are used to control bleeding in mild hemophilia and in some forms of von Willebrand disease.

How much does Eloctate cost?

The cost for Eloctate intravenous powder for injection recombinant fc fusion protein is around $12 for a supply of 1 powder for injection, depending on the pharmacy you visit….Intravenous Powder For Injection.

Quantity Per unit Price
1 $11.90 $11.90

Is advate a biologic?

Approval Status: Approved by the U.S. FDA on July 25, 2003. Chemical/Biological Nature: ADVATE is the molecularly engineered human Factor VIII glycoprotein consisting of 2,332 amino acids.

Who makes Kogenate?

Authorisation details

Publication details
Marketing-authorisation holder Bayer AG
Revision 30
Date of issue of marketing authorisation valid throughout the European Union 04/08/2000
Contact address Bayer AG 51368 Leverkusen Germany

author

Back to Top